Jun 12, 2023 / 05:40PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Great. Good morning, everyone. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're really pleased to have Gilead with us. So we have Dan O'Day, Chairman and CEO; as well as Merdad Parsey, CMO.
Questions and Answers:
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VPTo start here, maybe we'll start with some big picture questions. Can you just give us a 30,000-foot view of where the company stands today and where the challenges have been, the accomplishments and then how you think of kind of the forward from here?
Daniel P. O'Day - Gilead Sciences, Inc. - Chairman & CEO
Sure. So first of all, Salveen, great to be here with Merdad, and we're delighted to share some updates on Gilead. So at the 30,000-foot level, I think Merdad and I would say that we're really pleased with what's happened over the past 4 years. I mean just to remind you what our
Trustpilot
